Digital & Innovation
Pfizer strengthens position to ‘win the digital race in pharma’

Digital & Innovation: The last two years have highlighted the unique opportunity to increase and embed the use of digital health solutions to help patients achieve better health outcomes and a better healthcare experience.
Dr David Witcombe, Medical Affairs Lead for Inflammation and Immunology, Pfizer Australia joined Health Industry Hub to discuss how the organisation is enhancing patient care through digital health and connectivity.
David reflected on the evolution of the medical affairs function as a result of the digital transformation since the start of the pandemic.
He shared the potential impact for patients and healthcare professionals that results from connectivity through digital health technology, highlighting the recent launch of a new self-injecting device for Enbrel with a companion smartphone app which combines a medicine, medical device and digital health for rheumatoid arthritis patients.
David discussed the real world data captured from smartphone apps, wearable devices and other digital technologies accompanying medicines and therapies, and the significant potential to transform patient outcomes and provider better value for healthcare stakeholders.
Finally, he focussed on Pfizer’s broader strategy to “win the digital race in pharma” by leveraging smart technologies to enhance patient experiences and meet key stakeholder needs in a complex healthcare ecosystem.
News & Trends - MedTech & Diagnostics

Government’s claim of progress in genomics falls flat while it fails to uphold the fundamental rights of Aussies
The government has unveiled Cancer Australia’s National Framework for Genomics in Cancer Control, a strategic plan designed to guide healthcare […]
MoreNews & Trends - Pharmaceuticals

Healthcare sector’s political donations: What to expect ahead of the federal election
Ahead of the upcoming federal election, attention turns to the financial contributions to major political parties. The Australian Electoral Commission’s […]
MoreNews & Trends - Pharmaceuticals

‘Underinvestment in gynae cancer has left critical gaps,’ says ANZGOG Chair
Ovarian cancer is the deadliest women’s cancer, with the latest statistics revealing a five-year survival rate of just 49%. Alarmingly, […]
MoreNews & Trends - MedTech & Diagnostics

Labor’s one-off funding a band aid for public hospitals while private sector left in limbo
The Federal Government has committed a one-off funding boost of $1.7 billion to public hospitals under a one-year extension to […]
More